The Institute for Molecular Bioscience is Australia's #1 research institute. We were established to position Queensland as a global epicentre of drug discovery, and to create a full pipeline of capabilities from basic discovery science to translational research, spanning genomics, biology and chemistry.
Our vision is a world with a cure for every disease, and our partners are an integral part of this vision.
We have a track record of partnering to deliver translational outcomes. We have created multibillion-dollar spin-out companies developing treatments for stroke, Parkinson's disease and cancer, and helped deliver the world's first environmentally friendly pesticides to market.
IMB has the expertise and facilities to address globally relevant and organisation-specific research problems. We seek creative approaches to solve problems, and welcome the talent and ideas of our partners.
Our capabilites
We have a broad range of capabilities that span a number of research areas. In particular, we have expertise in:
- Pharmacogenomics
- Statistical genetics
- AI diagnostics
- Drug discovery
We are developing treatments and diagnostics, and discovering more about the fundamental biology, of the following diseases:
- AMR, with a focus on antibiotic discovery
- Cardiovascular disease
- Stroke
- Pain
- Endometriosis
- Cancer
- Non-alcoholic steatohepatitis (NASH)
- Amyotrophic lateral sclerosis/Motor neurone disease (ALS/MND)
To learn more about our capabilities and expertise in these areas, please contact our Research Partnership team.
Contact
Norbert Kienzle
partner@imb.uq.edu.au
Download our fast facts
Case study: Inflazome
One of the largest biotech deals in Australian history was the sale of a start-up company developing treatments for inflammatory diseases based on a research partnership between The University of Queensland, including IMB researchers, and Trinity College Dublin.
The company, Inflazome, was acquired by Swiss multinational pharma company Roche for an upfront payment of ~$A600 million, plus additional payments based on the achievement of certain milestones.
Inflazome was founded in 2016 to develop drugs to address clinical unmet needs in inflammatory diseases by targeting inflammasomes, protein complexes that are understood to drive many chronic inflammatory conditions. The acquisition gives Roche full rights to Inflazome’s portfolio of drugs, which includes candidates in clinical trials.
- UQ’s Community for Open Antimicrobial Drug Discovery (CO-ADD) has signed a Memorandum of Understanding (MOU) with the African Network for Drugs and Diagnostics Innovation (ANDI) which is hosted by the United Nations Office for Project Services (UNOPS).
- Researchers from The University of Queensland (UQ) are advancing their mission to discover new antibiotics capable of combating multi-drug resistant bacterial infections after signing an agreement to screen the entire French National Chemical Library.
- The Community for Open Antimicrobial Drug Discovery (CO-ADD) at The University of Queensland’s Institute for Molecular Bioscience (IMB) and the Innovative Medicines Initiative (IMI) ENABLE project have aligned to develop potential new antibiotics against multi-drug resistant bacterial infections.